Compare Noble Corporation plc (NE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Summit Therapeutics Inc — how do they compare? Noble Corporation plc trades at $43.43 (market cap $7.04B), while Summit Therapeutics Inc trades at $15.18 (market cap $12.06B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Noble Corporation plc pays a 4.54% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NE | SMMT | |
|---|---|---|
Market Cap | $7.04B | $12.06B |
Sector | Technology | Health |
52-Week High | $54.37 | $26.98 |
52-Week Low | $26.61 | $12.55 |
Enterprise Value | $8.47B | $11.39B |
Dividend Yield | 4.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $44.08, up 1.22% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, missing EPS estimates but securing $200 million in new contracts. Revenue and net income are trending lower year-over-year, with a P/E ratio of 47.32 indicating a premium valuation. Recent news highlights multiple law firm investigations into the company.
The outlook is cautious. While a $6.8 billion backlog and consistent dividends provide support, declining profitability, high valuation, and legal scrutiny present significant risks. Analyst consensus is a Hold with a $46.00 price target, suggesting limited near-term upside from current levels amid operational and sentiment headwinds.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
